Who has been buying Hana Pharmaceutical stock?

7 distinct insiders have filed 37 disclosed insider purchases in Hana Pharmaceutical (293480), most recently on 2026-06-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Hana Pharmaceutical have?

Hana Pharmaceutical has 37 buy-side and 1 sell-side disclosures on record, covering ₩1.9B ($1.3M) in total reported value, spanning 2024-02-01 to 2026-06-02.

Where does StockDrifts get Hana Pharmaceutical insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Hana Pharmaceutical 293480

Company

하나제약Hana Pharmaceutical

Insiders

Buys

Total Value

₩1.9B ($1.3M)

Avg Return

-5.32%

Last Filing

2026-06-02

Hana Pharmaceutical (293480) has 37 disclosed insider purchases and 1 disclosed disposals on record, filed by 7 distinct insiders. Together those filings cover ₩1.9B ($1.3M) in reported transaction value. The earliest filing StockDrifts holds for Hana Pharmaceutical is dated 2024-02-01; the most recent is 2026-06-02. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -5.32%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-02	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	23.9K	₩9,110	+0.0%	₩218M ($151K)
2026-06-01	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	218	₩9,360	-2.7%	₩2M ($1K)
2026-05-27	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	1.1K	₩9,690	-6.0%	₩11M ($7K)
2026-05-26	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	1.1K	₩9,970	-8.6%	₩11M ($7K)
2026-05-21	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	6.1K	₩10,010	-9.0%	₩61M ($42K)
2026-05-20	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	9.7K	₩9,830	-7.3%	₩96M ($66K)
2026-05-19	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	15.8K	₩9,980	-8.7%	₩158M ($110K)
2026-05-18	BUY	Market Buy	조예림 Yerim Cho	Managing Director	3.6K	₩9,850	-7.5%	₩35M ($25K)
2026-05-18	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	3.3K	₩9,850	-7.5%	₩33M ($23K)
2026-05-15	BUY	Market Buy	조예림 Yerim Cho	Managing Director	3.4K	₩9,430	-3.4%	₩32M ($22K)
2026-05-13	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	15.1K	₩9,260	-1.6%	₩140M ($97K)
2026-05-13	BUY	Market Buy	조예림 Yerim Cho	Managing Director	6.5K	₩9,260	-1.6%	₩60M ($42K)
2026-05-12	BUY	Market Buy	조예림 Yerim Cho	Managing Director	3.8K	₩9,270	-1.7%	₩35M ($24K)
2026-05-11	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	2.6K	₩9,650	-5.6%	₩25M ($17K)
2026-05-11	BUY	Market Buy	조예림 Yerim Cho	Managing Director	3.3K	₩9,650	-5.6%	₩32M ($22K)
2026-05-08	BUY	Market Buy	조예림 Yerim Cho	Managing Director	10.7K	₩9,630	-5.4%	₩103M ($72K)
2026-05-08	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	9.0K	₩9,630	-5.4%	₩87M ($60K)
2026-05-07	BUY	Market Buy	조예림 Yerim Cho	Managing Director	4.5K	₩9,770	-6.8%	₩44M ($30K)
2026-05-04	BUY	Market Buy	조예림 Yerim Cho	Managing Director	2.1K	₩9,850	-7.5%	₩21M ($14K)
2026-05-04	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	7.3K	₩9,850	-7.5%	₩72M ($50K)
2026-04-30	BUY	Market Buy	조예림 Yerim Cho	Managing Director	6.0K	₩9,810	-7.1%	₩59M ($41K)
2026-04-30	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	6.3K	₩9,810	-7.1%	₩62M ($43K)
2026-04-29	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	1.6K	₩9,920	-8.2%	₩16M ($11K)
2026-04-29	BUY	Market Buy	조예림 Yerim Cho	Managing Director	6.6K	₩9,920	-8.2%	₩65M ($45K)
2026-04-28	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	192	₩9,870	-7.7%	₩2M ($1K)
2026-04-28	BUY	Market Buy	조예림 Yerim Cho	Managing Director	773	₩9,870	-7.7%	₩8M ($5K)
2026-04-23	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	16.6K	₩9,570	-4.8%	₩159M ($110K)
2026-04-22	BUY	Market Buy	조혜림 Jo Hye-rim	vice president	3.3K	₩9,750	-6.6%	₩32M ($22K)
2026-02-12	BUY	Market Buy	이덕근 Deokgeun Lee	Managing Director of Production Department	1.0K	₩10,900	+0.5%	₩11M ($8K)
2026-02-06	BUY	Market Buy	이준원 Lee Jun-won	Head of Department/Managing Director	405	₩10,320	+6.1%	₩4M ($3K)
2026-02-06	BUY	Market Buy	이일기 Lee Il-gi	Outside director and audit committee member	1.1K	₩10,320	+6.1%	₩11M ($8K)
2026-01-06	SELL	Market Sell	이일기 Lee Il-gi	Outside director and audit committee member	-1.0K	₩10,900	-0.5%	₩11M ($8K)
2025-06-11	BUY	Market Buy	김상엽 Kim Sang-yeop	Executive director (executive director)	1.0K	₩12,140	-9.8%	₩12M ($8K)
2024-10-22	BUY	Market Buy	최태홍 Taehong Choi	CEO	10.0K	₩10,870	+0.7%	₩109M ($75K)
2024-08-06	BUY	Market Buy	김상엽 Kim Sang-yeop	CEO (each)	607	₩11,580	-5.4%	₩7M ($5K)
2024-08-05	BUY	Market Buy	이일기 Lee Il-gi	Outside director and audit committee member	268	₩11,280	-2.9%	₩3M ($2K)
2024-08-01	BUY	신규선임	김상엽 Kim Sang-yeop	CEO (each)	415	₩12,610	-13.2%	₩5M ($4K)
2024-07-02	BUY	Market Buy	이일기 Lee Il-gi	Outside director and audit committee member	1.7K	₩12,400	-11.7%	₩22M ($15K)
2024-02-01	BUY	Market Buy	이일기 Lee Il-gi	Outside director and audit committee member	1	₩13,410	-18.3%	₩13K ($9)

Frequently asked questions

Who has been buying Hana Pharmaceutical stock?: 7 distinct insiders have filed 37 disclosed insider purchases in Hana Pharmaceutical (293480), most recently on 2026-06-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Hana Pharmaceutical have?: Hana Pharmaceutical has 37 buy-side and 1 sell-side disclosures on record, covering ₩1.9B ($1.3M) in total reported value, spanning 2024-02-01 to 2026-06-02.
Where does StockDrifts get Hana Pharmaceutical insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Hana Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.